US obesity rates may be stabilizing as weight‑loss drug use rises

For decades the United States has seen a steady rise in obesity, with the Centers for Disease Control and Prevention reporting that more than 40 % of adults now carry excess weight. Recent surveys, however, hint at a reversal of that trend. The prescription of glucagon‑like peptide‑1 (GLP‑1) receptor agonists—most notably Ozempic (semaglutide) and its weight‑loss‑specific formulation Wegovy—has surged, with pharmacy data showing a 300 % increase in new prescriptions over the past year alone. The drugs, originally approved for type‑2 diabetes, have been repurposed for obesity after the Food and Drug Administration granted Wegovy approval in 2021.

Clinical trials and real‑world studies consistently report that semaglutide can produce 5 %–15 % total body weight loss after 12–24 weeks, and the drug’s safety profile is generally favorable, with nausea and constipation as the most common adverse events. In addition to pharmacologic effects, many patients report improved appetite control and reduced caloric intake. Cost and insurance coverage remain barriers, but insurers are increasingly covering the medication for patients with a body mass index above 30 or for those with comorbid conditions such as hypertension or type‑2 diabetes. Public health experts note that while individual outcomes are promising, the overall impact on national obesity prevalence will depend on broader access, adherence, and complementary lifestyle interventions.

In sum, the rapid uptick in Ozempic and Wegovy prescriptions signals a potential turning point in the obesity epidemic. Whether these medications will translate into a measurable decline in obesity rates nationwide hinges on sustained uptake, affordability, and integration with comprehensive weight‑management programs. Ongoing surveillance and long‑term studies will be essential to determine the drugs’ role in reversing the obesity trend.